156 related articles for article (PubMed ID: 37669868)
1. Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
Eyerich K; Gooderham MJ; Silvestre JF; Shumack SP; Mendes-Bastos P; Aoki V; Ortoncelli M; Silverberg JI; Teixeira HD; Chen SH; Calimlim BM; Takemoto S; Sancho C; Fritz B; Irvine AD
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):340-353. PubMed ID: 37669868
[TBL] [Abstract][Full Text] [Related]
2. Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study.
Gkalpakiotis S; Kannenberg S; Kingo K; Nada HR; Rakhmatulina MR; Lesiak A; Nicolescu AC; Darlenski R; Masri A; Zhou L; Albuquerque T; Hammad S; Almasry I
Dermatol Ther (Heidelb); 2024 May; 14(5):1173-1187. PubMed ID: 38702528
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
4. Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Guttman-Yassky E; Bar J; Rothenberg-Lausell C; Eichenfield L; Grada A; Abuabara K; Chapman M; Calimlim B; Wegzyn C; Gamelli A; Krueger W; Munoz B; Knapp K; Faller R; Crawford J; Silverberg J
J Drugs Dermatol; 2023 Apr; 22(4):344-354. PubMed ID: 37026893
[TBL] [Abstract][Full Text] [Related]
5. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis.
Anderson P; Austin J; Lofland JH; Piercy J; Joish VN
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1571-1585. PubMed ID: 34268709
[TBL] [Abstract][Full Text] [Related]
6. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.
Simpson EL; Guttman-Yassky E; Margolis DJ; Feldman SR; Qureshi A; Hata T; Mastey V; Wei W; Eckert L; Chao J; Arnold RJG; Yu T; Vekeman F; Suárez-Fariñas M; Gadkari A
JAMA Dermatol; 2018 Aug; 154(8):903-912. PubMed ID: 29971354
[TBL] [Abstract][Full Text] [Related]
7. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): Baseline treatment patterns and unmet needs assessment.
Wei W; Ghorayeb E; Andria M; Walker V; Schnitzer J; Kennedy M; Chen Z; Belland A; White J; Silverberg JI
Ann Allergy Asthma Immunol; 2019 Oct; 123(4):381-388.e2. PubMed ID: 31325566
[TBL] [Abstract][Full Text] [Related]
8. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
10. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults.
Simpson EL; Bieber T; Eckert L; Wu R; Ardeleanu M; Graham NM; Pirozzi G; Mastey V
J Am Acad Dermatol; 2016 Mar; 74(3):491-8. PubMed ID: 26777100
[TBL] [Abstract][Full Text] [Related]
11. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
Silverberg JI; Leshem YA; Calimlim BM; McDonald J; Litcher-Kelly L
Curr Med Res Opin; 2023 Oct; 39(10):1289-1296. PubMed ID: 37691437
[TBL] [Abstract][Full Text] [Related]
12. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
14. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
Silverberg JI; Simpson B; Abuabara K; Guttman-Yassky E; Calimlim B; Wegzyn C; Krueger W; Gamelli A; Munoz B; Faller RW; Crawford JM; Grada A; Eichenfield LF;
J Am Acad Dermatol; 2023 Sep; 89(3):519-528. PubMed ID: 37150299
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V
J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421
[TBL] [Abstract][Full Text] [Related]
16. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada.
de Bruin-Weller M; Gadkari A; Auziere S; Simpson EL; Puig L; Barbarot S; Girolomoni G; Papp K; Pink AE; Saba G; Werfel T; Eckert L
J Eur Acad Dermatol Venereol; 2020 May; 34(5):1026-1036. PubMed ID: 31587373
[TBL] [Abstract][Full Text] [Related]
17. Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry.
Silverberg JI; Pierce E; Feely M; Atwater AR; Schrader A; Jones EA; Dave SS; Simpson EL
J Dermatolog Treat; 2023 Dec; 34(1):2246601. PubMed ID: 37691405
[TBL] [Abstract][Full Text] [Related]
18. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
[TBL] [Abstract][Full Text] [Related]
19. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
[TBL] [Abstract][Full Text] [Related]
20. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
Rams A; Baldasaro J; Bunod L; Delbecque L; Strzok S; Meunier J; ElMaraghy H; Sun L; Pierce E
Adv Ther; 2024 Apr; 41(4):1512-1525. PubMed ID: 38363461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]